Phase I/II Study of the Safety and Efficacy of the AKT Inhibitor GSK2141795 in Combination with the BRAF Inhibitor Dabrafenib in Patients with BRAF Mutant Cancer

This phase I/II trial studies the side effects and the best dose of Akt inhibitor GSK2141795 (GSK2141795) when given together with dabrafenib and to see how well they work in treating patients with stage IIIC-IV cancer. Akt inhibitor GSK2141795 and dabrafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving Akt inhibitor GSK2141795 with dabrafenib may be an effective treatment for cancer.

Key Eligibility:

• For current phase of study: Patients must have BRAFV600 mutant metastatic cancer irrespective of the histology or prior therapy. For upcoming phase of study: Patients must have Stage IIIC or IV melanoma with BRAFV600 mutation

• Must have locally advanced unresectable Stage IIIC or metastatic Stage IV cancer with either progression to prior therapy or a newly diagnosed cancer that does not have an available treatment with curative intent.

• May have received prior systemic therapy (chemotherapy, immunotherapy, biologic therapy, or combination regimens). Patients progressing on a prior BRAF inhibitor-based therapy are eligible.
Phase I/II
Cutaneous (skin)
Alison Conlin, M.D.
Chris Fountain

The Pacific Cancer Research Consortium clinical trials are offered at multiple locations throughout Oregon, Washington, Alaska, California, and Idaho. To find a location near you, please contact the Patient Engagement Center at 844-552-2734.